Abstract:Therapy resistance is one of the most common underlying causes of poor prognosis in cancer patients, ultimately driving fatal outcome. We have previous demonstrated that following chemotherapeutic stress, a subset of cancer cells undergo a mitotic skip and enter an endocycle, causing whole-genome duplication without division. This endocycling cell state is resistant to cytotoxic therapies and thus is an actuator of therapy resistance. Cells in the endocycling state eventually undergo depolyploidization and repopulate the tumor, observed clinically as a recurrence. We also demonstrated that the minus-end directed motor protein KIFC1, a mediator of centrosome clustering, has higher expression in cells following treatment. Centrosome amplification (CA) involves aberrations in centrosome number, where cells have 3 centrosomes. Cells with extra centrosomes create a multi-polar spindle during mitosis, which presents high risk for cell death and arrest, but cancer cells with CA avoid this by clustering extra centrosomes to create a pseudo-bipolar spindle. Based upon this data, we hypothesize that studying centrosome dynamics and abnormalities presents a window into better understanding endocycle biology and this novel mechanism of therapy resistance. Cancer cells were treated with LD50 dose of cisplatin and released from treatment for varying lengths of time. CA in endocycling cells increased from 59.2% to 100% during the treatment recovery period while maintaining identical levels of clustering. Endocycling cancer cells have a nearly 5-fold increase in declustered centrosomes compared to proliferative cells. Centrosomes in endocycling cells are displaced from the perinuclear region and toward the cell periphery. We hypothesize that centrosome number may indicate the number of times a cell has endocycled and provide insight into the timing and mechanism of mitotic bypass. Centrosomes play a major role in microtubule nucleation, affecting cell motility and polarity, and act as signaling platforms, enhancing signaling activation and specificity. Because of this, we hypothesize that CA may be a critical mechanism for endocycling cancer cells to survive and maintain this resistant cell state. Citation Format: Madison Purkerson, Sarah Amend, Kenneth J. Pienta. Cancer cells in the resistant, endocycling cell state exhibit centrosome amplification [abstract]. In: Proceedings of the American Association for Cancer Research Annual Meeting 2024; Part 1 (Regular s); 2024 Apr 5-10; San Diego, CA. Philadelphia (PA): AACR; Cancer Res 2024;84(6_Suppl) nr 527.

A Look into the Link Between Centrosome Amplification and Breast Cancer

Centrosomes and associated proteins in pathogenesis and treatment of breast cancer

Centrosomal-associated Proteins: Potential therapeutic targets for solid tumors?

Chromosome aberrations associated with centrosome defects: a study of comparative genomic hybridization in breast cancer

Cancer‐associated Fibroblasts in Breast Cancer: Challenges and Opportunities

Amplified centrosomes—more than just a threat

Centromeres in cancer: Unraveling the link between chromosomal instability and tumorigenesis

[Centrosome Hyperamplificationin Oral Precancerous Lesions and Squamous Cell Carcinomas].

The Centrosome in Normal and Transformed Cells

Expression of centrosomal tubulins associated with DNA ploidy in breast premalignant lesions and carcinoma.

[Correlations of Centrosome Abnormality and Genomic Instability to Tumor].

Differential expression of centrosome regulators in Her2+ breast cancer cells versus non-tumorigenic MCF10A cells

[The Active Expression of CenpB, a Constitutive Protein in the Centromeres of Chromosomes, in Breast Cancer Tissues].

Discovery of Centrosomal Protein 70 As an Important Player in the Development and Progression of Breast Cancer.

Centrosome amplification primes ovarian cancer cells for apoptosis and potentiates the response to chemotherapy

Abstract 527: Cancer cells in the resistant, endocycling cell state exhibit centrosome amplification

Centrosome Dysfunction: a Link Between Senescence and Tumor Immunity

Overcome Cancer Drug Resistance by Targeting Epigenetic Modifications of Centrosome

Centrosome Dynamics and Its Role in Inflammatory Response and Metastatic Process

Oncogenic STIL-mediated loss of BRCA1 functionality causes DNA damage and centrosome amplification

Immune Infiltration Related CENPI Associates with the Malignant Features and Drug Resistance of Lung Adenocarcinoma.